Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18933687 | GENE THERAPY FOR RECESSIVE DYSTROPHIC EPIDERMOLYSIS BULLOSA USING GENETICALLY CORRECTED AUTOLOGOUS KERATINOCYTES | October 2024 | June 2025 | Allow | 7 | 2 | 0 | No | No |
| 18501837 | GENE THERAPY FOR RECESSIVE DYSTROPHIC EPIDERMOLYSIS BULLOSA USING GENETICALLY CORRECTED AUTOLOGOUS KERATINOCYTES | November 2023 | August 2024 | Allow | 10 | 2 | 1 | No | No |
| 18119201 | GENE THERAPY FOR NIEMANN-PICK DISEASE TYPE A | March 2023 | June 2025 | Abandon | 27 | 1 | 0 | Yes | No |
| 18152699 | VIRAL DELIVERY OF NEOANTIGENS | January 2023 | June 2025 | Abandon | 29 | 1 | 0 | No | No |
| 18145996 | RNA-Guided Systems for In Vivo Gene Editing | December 2022 | April 2025 | Allow | 28 | 1 | 0 | Yes | No |
| 18067283 | GENE THERAPY | December 2022 | April 2025 | Abandon | 28 | 1 | 0 | No | No |
| 18058126 | GENE THERAPY FOR TREATING FAMILIAL HYPERCHOLESTEROLEMIA | November 2022 | May 2025 | Abandon | 29 | 1 | 0 | No | No |
| 18057572 | GENE THERAPY FOR TREATING CITRULLENEMIA | November 2022 | April 2025 | Allow | 28 | 1 | 0 | No | No |
| 17976062 | GENE DELIVERY SYSTEM CONTAINING RELAXIN GENE AND PHARMACEUTICAL COMPOSITION USING RELAXIN | October 2022 | April 2025 | Abandon | 29 | 1 | 0 | No | No |
| 17663242 | SYNP88, A PROMOTER FOR THE EXPRESSION OF GENES | May 2022 | February 2025 | Abandon | 33 | 1 | 0 | No | No |
| 17577940 | ADMINISTRATION OF TUMOR INFILTRATING LYMPHOCYTES WITH MEMBRANE BOUND INTERLEUKIN 15 TO TREAT CANCER | January 2022 | February 2024 | Abandon | 25 | 4 | 0 | No | No |
| 17646212 | DHFR TUNABLE PROTEIN REGULATION | December 2021 | May 2024 | Allow | 28 | 5 | 1 | No | No |
| 17545632 | METHODS FOR EXTENDING THE REPLICATIVE CAPACITY OF SOMATIC CELLS DURING AN EX VIVO CULTIVATION PROCESS | December 2021 | November 2024 | Abandon | 35 | 0 | 1 | No | No |
| 17543148 | CHIMERIC ANTIGEN RECEPTORS TARGETING HER2 | December 2021 | February 2025 | Abandon | 38 | 0 | 1 | No | No |
| 17478488 | INDUCED ACTIVATION IN DENDRITIC CELLS | September 2021 | December 2024 | Abandon | 39 | 1 | 0 | No | No |
| 17472284 | DRUG REGULATED TRANSGENE EXPRESSION | September 2021 | October 2024 | Allow | 38 | 1 | 0 | Yes | No |
| 17407782 | INTRATHECAL ADMINISTRATION OF ADENO-ASSOCIATED-VIRAL VECTORS FOR GENE THERAPY | August 2021 | May 2025 | Abandon | 44 | 1 | 1 | No | No |
| 17403138 | Hepatocyte Based Insulin Gene Therapy for Diabetes | August 2021 | August 2024 | Allow | 36 | 1 | 0 | No | No |
| 17401474 | NUCLEATED CELL PRESERVATION BY LYOPHILIZATION | August 2021 | October 2024 | Abandon | 38 | 0 | 1 | No | No |
| 17385265 | IMMUNOMODULATORY ONCOLYTIC ADENOVIRAL VECTORS, AND METHODS OF PRODUCTION AND USE THEREOF FOR TREATMENT OF CANCER | July 2021 | September 2024 | Abandon | 38 | 1 | 0 | No | No |
| 17365845 | AAV VECTOR FOR TREATMENT OF FRIEDREICH'S ATAXIA | July 2021 | June 2025 | Abandon | 47 | 3 | 0 | No | No |
| 17356214 | COMPOSITIONS AND METHODS FOR DELIVERING CFTR POLYPEPTIDES | June 2021 | July 2024 | Abandon | 37 | 1 | 0 | No | No |
| 17240714 | Methods and Compositions Related to Annexin 1-Binding Compounds | April 2021 | September 2024 | Abandon | 41 | 1 | 1 | No | No |
| 17224524 | HUMANIZED RODENTS THAT EXPRESS HEAVY CHAIN CONTAINING VL DOMAINS | April 2021 | July 2024 | Abandon | 39 | 1 | 0 | No | No |
| 17222659 | ADENO-ASSOCIATED VIRUS COMPOSITIONS FOR IDS GENE TRANSFER AND METHODS OF USE THEREOF | April 2021 | April 2024 | Abandon | 37 | 1 | 1 | No | No |
| 17276112 | MODIFIED MRNA FOR THE TREATMENT OF PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS DISORDERS | March 2021 | February 2025 | Abandon | 47 | 1 | 1 | No | No |
| 17200725 | ONCOLYTIC VACCINIA VIRUS CANCER THERAPY | March 2021 | May 2024 | Abandon | 38 | 0 | 1 | No | No |
| 17143019 | RECOMBINANT PROMOTERS AND VECTORS FOR PROTEIN EXPRESSION IN LIVER AND USE THEREOF | January 2021 | July 2024 | Abandon | 42 | 1 | 0 | No | No |
| 17134483 | COMPOSITIONS FOR CONFERRING TOLERANCE TO VIRAL DISEASE IN SOCIAL INSECTS, AND THE USE THEREOF | December 2020 | June 2024 | Abandon | 41 | 1 | 0 | No | No |
| 17131688 | HIGH AFFINITY MAGE-A1-SPECIFIC TCRS AND USES THEREOF | December 2020 | February 2024 | Abandon | 38 | 1 | 0 | No | No |
| 17120743 | MODULATION OF TISSUE FATTY ACID COMPOSITION OF A HOST BY HUMAN GUT BACTERIA | December 2020 | February 2024 | Abandon | 38 | 1 | 0 | No | No |
| 17116168 | RECOMBINANT AAVS HAVING USEFUL TRANSCYTOSIS PROPERTIES | December 2020 | May 2024 | Abandon | 41 | 2 | 0 | No | No |
| 17116098 | Adeno Associated Virus Vectors for the Treatment of Hunter Disease | December 2020 | September 2023 | Allow | 33 | 1 | 1 | Yes | No |
| 17105022 | BRAIN REPAIR AFTER TRAUMATIC BRAIN INJURY THROUGH NEUROD1-MEDIATED ASTROCYTE-TO-NEURON CONVERSION | November 2020 | May 2025 | Abandon | 54 | 4 | 1 | No | No |
| 17099942 | RODENTS HAVING A HUMANIZED TMPRSS GENE | November 2020 | October 2023 | Allow | 35 | 1 | 0 | No | No |
| 17092239 | RECOMBINANT ADENO-ASSOCIATED VIRAL VECTOR FOR GENE DELIVERY | November 2020 | August 2024 | Allow | 46 | 3 | 1 | No | No |
| 17053198 | BLOOD PRODUCT DERIVED FROM GENE KNOCKOUT PIG AND USE THEREOF | November 2020 | August 2024 | Abandon | 45 | 1 | 1 | No | No |
| 17051197 | RAAV-MEDIATED NUCLEASE-ASSOCIATED VECTOR INTEGRATION (RAAV-NAVI) | October 2020 | July 2024 | Abandon | 45 | 1 | 1 | No | No |
| 17079380 | METHODS AND AGENTS FOR ENHANCING T CELL THERAPIES | October 2020 | February 2024 | Abandon | 40 | 2 | 1 | No | No |
| 17069305 | METHODS AND COMPOSITIONS FOR LOCALIZED AGENT DELIVERY | October 2020 | May 2024 | Abandon | 43 | 1 | 1 | No | No |
| 17024424 | ANTIBODY GENE THERAPY FOR TREATMENT AND PREVENTION OF INFECTION BY RABIES LYSSAVIRUS | September 2020 | June 2025 | Abandon | 57 | 4 | 1 | No | No |
| 17021526 | NUCLEIC ACID CONSTRUCTS COMPRISING GENE EDITING MULTI-SITES AND USES THEREOF | September 2020 | February 2025 | Abandon | 53 | 4 | 0 | No | No |
| 17015925 | Functionalized DNA Dendrimers For Gene Delivery To Cells | September 2020 | February 2024 | Abandon | 42 | 2 | 0 | No | No |
| 16971801 | SEQUENCING METHOD FOR CAR T CELL THERAPY | August 2020 | September 2024 | Allow | 49 | 1 | 1 | Yes | No |
| 16992689 | GENE AUGMENTATION THERAPIES FOR INHERITED RETINAL DEGENERATION CAUSED BY MUTATIONS IN THE PRPF31 GENE | August 2020 | December 2024 | Abandon | 52 | 2 | 1 | No | Yes |
| 16989454 | Ancestral Virus Sequences and Uses Thereof | August 2020 | May 2024 | Allow | 45 | 3 | 0 | Yes | No |
| 16900178 | METHODS AND COMPOSITIONS FOR NON-CYTOTOXIC STEM CELL TRANSPLANTATION | June 2020 | March 2024 | Abandon | 46 | 7 | 0 | Yes | Yes |
| 16870445 | COMPOSITIONS TO DISRUPT PROTEIN KINASE A ANCHORING AND USES THEREOF | May 2020 | April 2024 | Abandon | 48 | 2 | 1 | No | No |
| 16809300 | ANALYSIS OF GENOMIC DNA, RNA, AND PROTEINS IN EXOSOMES FOR DIAGNOSIS AND THERANOSIS | March 2020 | May 2024 | Abandon | 50 | 2 | 1 | No | No |
| 16797527 | GENE THERAPY TO IMPROVE VISION | February 2020 | June 2025 | Abandon | 60 | 4 | 1 | No | No |
| 16637447 | METHODS AND COMPOSITIONS FOR PREPARING GENETICALLY ENGINEERED CELLS | February 2020 | May 2024 | Abandon | 51 | 3 | 1 | No | No |
| 16743772 | TARGETING CYTOTOXIC CELLS WITH CHIMERIC RECEPTORS FOR ADOPTIVE IMMUNOTHERAPY | January 2020 | December 2023 | Allow | 47 | 4 | 1 | No | No |
| 16616713 | CBLB ENDONUCLEASE VARIANTS, COMPOSITIONS, AND METHODS OF USE | November 2019 | September 2024 | Allow | 58 | 5 | 1 | Yes | No |
| 16613907 | GENE THERAPY FOR TUBEROUS SCLEROSIS | November 2019 | December 2023 | Allow | 49 | 3 | 0 | Yes | No |
| 16604675 | MULTIPLE TRANSGENE RECOMBINANT ADENOVIRUS | October 2019 | February 2024 | Allow | 53 | 4 | 1 | No | No |
| 16604475 | ADENO-ASSOCIATED VIRUS LIBRARY | October 2019 | April 2024 | Abandon | 55 | 3 | 1 | No | No |
| 16498592 | OXIDATION-RESISTANT AAT GENE THERAPY | September 2019 | February 2024 | Allow | 53 | 4 | 1 | Yes | No |
| 16495826 | Gene Therapy for the Treatment of CNGB1-linked Retinitis Pigmentosa | September 2019 | November 2024 | Allow | 60 | 5 | 1 | No | No |
| 16482049 | TUMOR SELECTIVE TATA-BOX AND CAAT-BOX MUTANTS | July 2019 | April 2025 | Abandon | 60 | 6 | 1 | No | No |
| 16513566 | METHODS AND COMPOSITIONS OF OTC CONSTRUCTS AND VECTORS | July 2019 | June 2025 | Abandon | 60 | 3 | 1 | No | Yes |
| 16477168 | POLYNUCLEOTIDES AND VECTORS FOR THE EXPRESSION OF TRANSGENES | July 2019 | November 2023 | Allow | 52 | 4 | 1 | No | No |
| 16475926 | GENETICALLY MODIFIED NK-92 CELLS WITH DECREASED CD96/TIGIT EXPRESSION | July 2019 | November 2024 | Abandon | 60 | 6 | 1 | Yes | Yes |
| 16456773 | RNA VIRUSES EXPRESSING IL-12 FOR IMMUNOVIROTHERAPY | June 2019 | August 2023 | Abandon | 49 | 5 | 1 | No | Yes |
| 16428348 | METHODS FOR GENOME-EDITING AND ACTIVATION OF CELLS | May 2019 | June 2024 | Abandon | 60 | 4 | 1 | No | No |
| 16290357 | COMPOSITIONS FOR DELIVERY OF CARGO TO CELLS | March 2019 | December 2024 | Abandon | 60 | 7 | 0 | No | No |
| 16253056 | Immunomodulatory Oncolytic Adenoviral Vectors, and Methods of Production and Use Thereof for Treatment of Cancer | January 2019 | February 2024 | Abandon | 60 | 4 | 1 | No | No |
| 16250679 | METHODS OF ASSESSING POTENCY OF VIRAL VECTORS | January 2019 | October 2024 | Abandon | 60 | 6 | 0 | Yes | No |
| 16315362 | AAV2-MEDIATED GENE DELIVERY OF SFASL AS A NEUROPROTECTIVE THERAPY IN GLAUCOMA | January 2019 | June 2024 | Abandon | 60 | 4 | 1 | No | Yes |
| 16308196 | A NOVEL ROLE FOR TERMINAL RNA URIDYLATION AND RNA TURNOVER IN ONCOGENESIS | December 2018 | December 2024 | Abandon | 60 | 4 | 1 | Yes | No |
| 16307462 | METHODS FOR THE TREATMENT OF B CELL MALIGNANCIES USING ADOPTIVE CELL THERAPY | December 2018 | February 2025 | Abandon | 60 | 6 | 1 | No | No |
| 16091967 | USE OF HETERODIMERIC IL-15 IN ADOPTIVE CELL TRANSFER | October 2018 | September 2024 | Abandon | 60 | 6 | 0 | No | No |
| 16066253 | GENE THERAPY FOR RECESSIVE DYSTROPHIC EPIDERMOLYSIS BULLOSA USING GENETICALLY CORRECTED AUTOLOGOUS KERATINOCYTES | June 2018 | October 2024 | Allow | 60 | 9 | 1 | Yes | No |
| 15771683 | USE OF MAPK INHIBITORS TO REDUCE LOSS OF HEMATOPOIETIC STEM CELLS DURING EX VIVO CULTURE AND/OR GENETIC MANIPULATION | April 2018 | June 2025 | Abandon | 60 | 6 | 1 | Yes | Yes |
| 15771849 | Gene Therapy | April 2018 | June 2024 | Abandon | 60 | 8 | 0 | Yes | Yes |
| 15753003 | BAG3 COMPOSITIONS AND METHODS | February 2018 | June 2024 | Abandon | 60 | 8 | 0 | Yes | No |
| 15838824 | TLR AGONISTS FOR REDUCING ACTIVATION-INDUCED PD-1 EXPRESSION ON T CELLS AND METHODS OF USE | December 2017 | April 2024 | Abandon | 60 | 7 | 0 | No | No |
| 15557263 | IL-10-PRODUCING CD4+ T CELLS AND USES THEREOF | September 2017 | March 2025 | Abandon | 60 | 8 | 1 | Yes | Yes |
| 15552163 | SITE-SPECIFIC INTEGRATING RECOMBINANT AAV VECTORS FOR GENE THERAPY AND IMPROVED PRODUCTION METHODS | August 2017 | September 2024 | Abandon | 60 | 7 | 1 | Yes | No |
| 15520633 | TRIPLE TRANSGENIC PIGS SUITABLE FOR XENOGRAFT | April 2017 | July 2024 | Abandon | 60 | 6 | 1 | Yes | Yes |
| 15259797 | METHODS AND COMPOSITIONS FOR THE PACKAGING OF NUCLEIC ACIDS INTO MICROGLIAL EXOSOMES FOR THE TARGETED EXPRESSION OF POLYPEPTIDES IN NEURAL CELLS | September 2016 | September 2017 | Allow | 12 | 0 | 1 | No | No |
| 14846952 | METHODS AND COMPOSITIONS FOR ATTENUATING GENE THERAPY ANTI-VIRAL TRANSFER VECTOR IMMUNE RESPONSES | September 2015 | January 2025 | Abandon | 60 | 11 | 1 | No | Yes |
| 14772361 | Placental Like Alkaline Phosphatase (PLAP) Promoter Mediated Cell Targeting | September 2015 | June 2017 | Allow | 22 | 3 | 1 | Yes | No |
| 14763283 | APTAMERS FOR TUMOR INITIATING CELLS | July 2015 | November 2016 | Allow | 16 | 1 | 1 | Yes | No |
| 14740890 | SEQUENCE OF NUCLEOTIDES AND PEPTIDES GSE 24.2 OF DYSKERIN, WHICH CAN INDUCE TELOMERASE ACTIVITY, METHOD FOR OBTAINING SAME, THERAPEUTIC COMPOSITIONS AND APPLICATIONS THEREOF | June 2015 | November 2016 | Allow | 17 | 1 | 1 | No | No |
| 14492334 | MANNOSE-CONTAINING SOLUTION FOR LYOPHILIZATION, TRANSFECTION AND/OR INJECTION OF NUCLEIC ACIDS | September 2014 | December 2016 | Allow | 26 | 2 | 1 | No | No |
| 14289043 | Soft Tissue and Bone Augmentation and Bulking Utilizing Muscle-Derived Progenitor Cells, Compositions and Treatments Thereof | May 2014 | May 2016 | Allow | 24 | 1 | 1 | No | No |
| 14242648 | NOVEL VIRAL VECTOR CONSTRUCT FOR NEURON SPECIFIC OPTIMIZED CONTINUOUS DOPA SYNTHESIS IN VIVO | April 2014 | November 2016 | Allow | 33 | 2 | 1 | Yes | No |
| 14220099 | ANIMALS, REPERTOIRES & METHODS | March 2014 | March 2024 | Abandon | 60 | 10 | 1 | No | No |
| 14161656 | SMALL MOLECULES SUPPORTING PLURIPOTENT CELL GROWTH AND METHODS THEREOF | January 2014 | May 2016 | Allow | 28 | 1 | 1 | Yes | No |
| 13613338 | BRANCHED POLYAMINES FOR DELIVERY OF BIOLOGICALLY ACTIVE MATERIALS | September 2012 | November 2013 | Allow | 14 | 0 | 1 | No | No |
| 13511353 | T CELL RECEPTORS SPECIFIC FOR IMMUNODOMINANT CTL EPITOPES OF HCV | August 2012 | November 2013 | Allow | 18 | 1 | 1 | Yes | No |
| 13543059 | STEM CELL CAPTURE AND IMMOBILIZATION COATINGS FOR MEDICAL DEVICES AND IMPLANTS | July 2012 | April 2013 | Allow | 9 | 1 | 0 | Yes | No |
| 13514913 | METHOD FOR DIAGNOSIS/PROGNOSIS OF CANCERS USING AN EPIGENETIC MARKER CONSISTING OF A SPECIFIC SINGLE CPG SITE IN TTP PROMOTER AND TREATMENT OF CANCERS BY REGULATING ITS EPIGENETIC STATUS | June 2012 | December 2013 | Allow | 18 | 1 | 1 | Yes | No |
| 13384435 | THERAPEUTIC AGENTS | May 2012 | October 2013 | Allow | 21 | 1 | 1 | Yes | No |
| 13301475 | COMPOSITIONS AND METHODS FOR REGULATING ANGIOGENESIS | November 2011 | March 2015 | Allow | 40 | 2 | 1 | Yes | No |
| 13259151 | SMALL MOLECULES SUPPORTING PLURIPOTENT CELL GROWTH AND METHODS THEREOF | September 2011 | October 2013 | Allow | 25 | 2 | 1 | Yes | No |
| 13038827 | SOFT TISSUE AND BONE AUGMENTATION AND BULKING UTILIZING MUSCLE-DERIVED PROGENITOR CELLS, COMPOSITIONS AND TREATMENTS THEREOF | March 2011 | November 2013 | Allow | 32 | 3 | 0 | No | No |
| 12681243 | NOVEL PROTEIN TRANSDUCTION DOMAINS DERIVED FROM SECRETORY LEUKOCYTE PROTEASE INHIBITOR | December 2010 | July 2013 | Allow | 40 | 1 | 1 | Yes | No |
| 12993517 | Method For Characterising The Biological Activity Of Helminth Eggs, In Particular Trichuris Eggs | December 2010 | December 2014 | Allow | 48 | 2 | 1 | Yes | No |
| 12952863 | MODULATION OF IMMUNOSTIMULATORY PROPERTIES OF OLIGONUCLEOTIDE-BASED COMPOUNDS BY UTILIZING MODIFIED IMMUNOSTIMULATORY DINUCLEOTIDES | November 2010 | February 2012 | Allow | 14 | 1 | 1 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner HILL, KEVIN KAI.
With a 33.3% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 17.6% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner HILL, KEVIN KAI works in Art Unit 1638 and has examined 130 patent applications in our dataset. With an allowance rate of 53.1%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 44 months.
Examiner HILL, KEVIN KAI's allowance rate of 53.1% places them in the 9% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by HILL, KEVIN KAI receive 3.03 office actions before reaching final disposition. This places the examiner in the 96% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.
The median time to disposition (half-life) for applications examined by HILL, KEVIN KAI is 44 months. This places the examiner in the 2% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +46.7% benefit to allowance rate for applications examined by HILL, KEVIN KAI. This interview benefit is in the 93% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 12.7% of applications are subsequently allowed. This success rate is in the 4% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 35.2% of cases where such amendments are filed. This entry rate is in the 45% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.
When applicants request a pre-appeal conference (PAC) with this examiner, 0.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 1% percentile among all examiners. Note: Pre-appeal conferences show limited success with this examiner compared to others. While still worth considering, be prepared to proceed with a full appeal brief if the PAC does not result in favorable action.
This examiner withdraws rejections or reopens prosecution in 57.1% of appeals filed. This is in the 24% percentile among all examiners. Of these withdrawals, 50.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner rarely withdraws rejections during the appeal process compared to other examiners. If you file an appeal, be prepared to fully prosecute it to a PTAB decision. Per MPEP § 1207, the examiner will prepare an Examiner's Answer maintaining the rejections.
When applicants file petitions regarding this examiner's actions, 81.6% are granted (fully or in part). This grant rate is in the 93% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 11.5% of allowed cases (in the 97% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 2.9% of allowed cases (in the 71% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.